Market Cap (In SEK)
56.56 Million
Revenue (In SEK)
1.35 Million
Net Income (In SEK)
-41.43 Million
Avg. Volume
7.71 Million
- Currency
- SEK
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 5.166666-112.72727
- PE
- -
- EPS
- -
- Beta Value
- 0.692
- ISIN
- SE0014684569
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Mr. Fredrik Rickman
- Employee Count
- -
- Website
- https://www.prostatypegenomics.com
- Ipo Date
- 2020-11-03
- Details
- Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. It offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, Gleason Score, and Tumor Stage, as well as calculates the P-score. The test is based on database containing prostate cancer patients and provides decision support for patients and doctors when making a treatment decision. The company was founded in 2007 and is based in Solna, Sweden.
More Stocks
-
NDO
-
UCIXUmbra Companies Inc.
UCIX
-
SYBLYSybly Industries Limited
SYBLY
-
BARK-WTBARK, Inc.
BARK-WT
-
VARDMNPOLYVardhman Polytex Limited
VARDMNPOLY
-
ORINOrian Sh.M. Ltd.
ORIN
-
ARESF
-
MNIF